The wound care company Odinwell reports, as planned, no revenue in the fourth quarter. The operating loss decreased. The board proposes no dividend. "During the year we also analyzed the possibilities of using our technology in veterinary medicine. During the autumn it became clear that our existing demo products and software have a sufficient level of maturity to move toward commercialization in this segment. Therefore, in 2026 we will focus on validating and preparing the handheld scanner for market introduction in veterinary medicine," says CEO Marcus Andersson. The operating result was -SEK 1.2 million (-1.4). The result after tax was -SEK 1.1 million (-1.1). Earnings per share amounted to -SEK 0.02 (-0.05). No ordinary dividend is proposed (0).Odinwell, SEK millionQ4-2025Q4-2024Net sales00Operating result-1.2-1.4Net result-1.1-1.1Earnings per share, SEK-0.02-0.05Ordinary annual dividend per share, SEK00